NCT04726501Active, not recruitingPhase 4
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage" and extremely low incidence, it has brought great difficulties to the domestic clinical research and failed to achieve the desired effect. In this study, we apply a well-documented effective protocol on newly diagnosed children and adolescents with HL to understand whether the same treatment regimens can obtain similar event free survival rates and overall survival rates and then find out the problems existing in the current clinical care of HL in China, so as to make continuous improvement in the future and prepare for innovative clinical research.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 23 Jan 2021
- Start date
- 1 Apr 2018
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Children's Cancer Group, China
- Diseases
- Hodgkin lymphoma, Childhood cancers
- NCT number
- NCT04726501
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 200
- From 1 Apr 2018 to the primary completion date, 31 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients have received prior cytotoxic chemotherapy for the current diagnosis or any cancer, if any steroid applied, total prior steroids dosage \< Prednisone 80 mg/m2; Patients have congenital immunodeficiency, HIV infection, or prior organ transplant; Patients have overwhelming infection, and a life expectancy of \< 2 weeks
Who the study is looking for
- Patient must be ages 1 to 18 years at the time of diagnosis; Newly diagnosed, histologically confirmed Hodgkin disease (No nodular lymphocyte-predominant Hodgkin lymphoma)
Age in the registry: 1 year to 18 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Second University Hospital, Sichuan University, Chengdu, China Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Shanghai Children's Medical Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.